Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.
D'Onofrio R, Sperduti I, Piacentini F, Barbolini M, Omarini C, Toss A, Cortesi L, Barbieri E, Canino F, Dominici M, Moscetti L. D'Onofrio R, et al. Among authors: moscetti l. Clin Breast Cancer. 2023 Dec;23(8):e534-e541. doi: 10.1016/j.clbc.2023.09.002. Epub 2023 Sep 9. Clin Breast Cancer. 2023. PMID: 37775349 Review.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S. Di Costanzo F, et al. Among authors: moscetti l. Br J Cancer. 2005 Jul 25;93(2):185-9. doi: 10.1038/sj.bjc.6602640. Br J Cancer. 2005. PMID: 15986036 Free PMC article. Clinical Trial.
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A, Carlini P, Ruggeri EM, Gamucci T, Pollera CF, De Marco S, Fariello AM, Moscetti L, Gelibter A, Adami E, Sperduti I, Cognetti F. Felici A, et al. Among authors: moscetti l. Cancer Chemother Pharmacol. 2006 Jan;57(1):59-64. doi: 10.1007/s00280-005-0032-5. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16001173 Clinical Trial.
Rhabdomyolysis from erlotinib: a case report.
Moscetti L, Nelli F, Ruggeri EM. Moscetti L, et al. Tumori. 2011 May-Jun;97(3):415-6. doi: 10.1177/030089161109700327. Tumori. 2011. PMID: 21789026 No abstract available.
118 results